Modulation of Cerebral Blood Flow Using Iron Chelators
- Registration Number
- NCT01365104
- Lead Sponsor
- Brigham and Women's Hospital
- Brief Summary
The purpose of this study is determine if the iron chelator, desferrioxamine can increase blood levels of hypoxia-inducible transcription factor 1 (HIF-1 protein) and to see if there is a corresponding increase in blood flow to the brain.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 97
- healthy adults between the ages of 18-80 years.
- subjects taking vasoactive medications,
- hypertension,
- pregnant women, smokers,
- COPD,
- asthma,
- diabetes mellitus,
- intracranial or carotid stenosis,
- hepatic disease,
- renal disease,
- bone marrow suppression,
- cardiac disease,
- heart failure,
- iron deficiency,
- history of cancer,
- history of head trauma,
- subarachnoid hemorrhage,
- central nervous system vasculitis,
- multiple sclerosis,
- migraines,
- seizures,
- sickle cell disease or trait,
- cardiac arrhythmia,
- unable to give informed consent, or
- poor transcranial Doppler insonation windows.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Healthy young desferrioxamine Each subject comes for 2 visits. There is a randomized, double-blind, crossover design so each subject will receive active drug during one visit and placebo during the other. healthy old desferrioxamine Each subject comes for 2 visits. There is a randomized, double-blind, crossover design so each subject will receive active drug during one visit and placebo during the other.
- Primary Outcome Measures
Name Time Method Define change from baseline cerebral blood flow after receiving DFO infusion. baseline, 3hr, 6hr, 9hr Cerebral blood flow is measured with transcranial Doppler ultrasound at baseline and then study drug is initiated. Blood flow is measured again after 3 hours of infusion, 6 hours of infusion, then once more 3 hours after the infusion is complete.
Determine if DFO changes blood HIF-1 levels from baseline and whether this correlates with changes in cerebrovascular hemodynamics. baseline, 3hr, 6hr, 9hr Blood samples are taken at each time point and will be correlated with ultrasound blood flow measures taken at baseline, 3hrs of infusion, 6hrs of infusion, and 3 hours after infusion is complete.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Brigham and Women's Hospital
🇺🇸Boston, Massachusetts, United States